Skip to content

Anxiety: all studies

Page 258 of 773: studies 2,571 to 2,580 of 7,721, newest first. Back to the anxiety overview

Research

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder.

Journal of Affective Disorders September 1, 2020 Emily M LaFrance, Nicholas C. Glodosky, Marcel O Bonn-Miller et al.

Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of...

Testing the Efficacy of a Multicomponent, Self-Guided, Smartphone-Based Meditation App: Three-Armed Randomized Controlled Trial (Preprint)

August 28, 2020 Simon B. Goldberg, Ted Imhoff‐Smith, Daniel M. Bolt et al.

BACKGROUND A growing number of randomized controlled trials (RCTs) suggest psychological benefits associated with meditation training delivered via mobile health. However, research in this area has primarily focused on mindfulness, only one of many meditative techniques. OBJECTIVE This study aims to evaluate the efficacy of 2 versions of a self-guided, smartphone-based meditation app—the...

The Antidepressant Effect of Ketamine Is Dampened by Concomitant Benzodiazepine Medication

Frontiers in Psychiatry August 28, 2020 Veronika Andrashko, Tomáš Novák, Martin Brunovský et al. 46 citations

The rapid antidepressant effect of ketamine has become a breakthrough in the research and treatment of depression. Although predictive and modulating factors of the response to ketamine are broadly studied, little is known about optimal concurrent medication protocols. Concerning gamma-aminobutyric acid neurotransmission being a shared target for both ketamine and benzodiazepines (BZD), we...

A low dose of lysergic acid diethylamide decreases pain perception in healthy volunteers

Journal of Psychopharmacology August 25, 2020 Johannes G. Ramaekers, Nadia R. P. W. Hutten, Natasha L. Mason et al. 95 citations

Background: Lysergic acid diethylamide (LSD) is an ergot alkaloid derivative with psychedelic properties that has been implicated in the management of persistent pain. Clinical studies in the 1960s and 1970s have demonstrated profound analgesic effects of full doses of LSD in terminally ill patients, but this line of research evaporated after LSD was scheduled worldwide. Aim: The present...

Reframing Bummer Trips: Scientific and Cultural Explanations to Adverse Reactions to Psychedelic Drug Use

The Social History of Alcohol and Drugs August 20, 2020 Erika Dyck, Chris Elcock 28 citations

The concept of a bad or bummer trip has been used to capture the imagination of public health advisors and drug regulators, especially for producing warnings against taking drugs that cause physical and psychological harm. Psychedelics emerged in the 1960s public health literature as frequently causing bad trips, with violent and fearful outbursts from users causing harm to themselves and...

DOI: 10.1086/707512 (opens in new tab) Anxiety Trips architecture Harm Criminology +3

Analogy between classical Yoga/Zen breathing and modern clinical respiratory therapy.

Journal of Anesthesia August 17, 2020 Masaru Tobe, Shigeru Saito

Anesthesiologists and intensivists are modern-day professionals who provide appropriate respiratory care, vital for patient survival. Recently, anesthesiologists have increasingly focused their attention on the type of spontaneous breathing made by non-intubated patients with pulmonary disease cared for in an intensive care unit, and also patients with chronic pain receiving cognitive...

Post-Psychedelic Reductions in Experiential Avoidance Are Associated With Decreases in Depression Severity and Suicidal Ideation

Frontiers in Psychiatry August 7, 2020 Richard J. Zeifman, Anne Catherine Wagner, Ros Watts et al. 104 citations

Psychedelic therapy shows promise as a novel intervention for a wide range of mental health concerns but its therapeutic action is incompletely understood. In line with acceptance and commitment therapy's (ACT's) transdiagnostic model, qualitative research has suggested that reductions in experiential avoidance are an important component of therapeutic outcomes associated with psychedelics....

DOI: 10.3389/fpsyt.2020.00782 (opens in new tab) Anxiety Suicidal ideation Experiential avoidance Depression economics +5

Acute effects of cannabinoids on symptoms of obsessive-compulsive disorder: A human laboratory study.

Depression and Anxiety August 1, 2020 Reilly R Kayser, Margaret Haney, Marissa Raskin et al.

Preclinical data implicate the endocannabinoid system in the pathology underlying obsessive-compulsive disorder (OCD), while survey data have linked OCD symptoms to increased cannabis use. Cannabis products are increasingly marketed as treatments for anxiety and other OCD-related symptoms. Yet, few studies have tested the acute effects of cannabis on psychiatric symptoms in humans. We recruited...

Effects of Chronic Exposure to Low-Dose delta-9-Tetrahydrocannabinol in Adolescence and Adulthood on Serotonin/Norepinephrine Neurotransmission and Emotional Behavior

The International Journal of Neuropsychopharmacology July 23, 2020 Danilo de Gregorio, Joshua Dean Conway, Martha López-canul et al. 39 citations

BACKGROUND: Chronic exposure to the Δ9-tetrahydrocannabinol (THC), the main cannabis pharmacological component, during adolescence has been shown to be associated with an increased risk of depression and suicidality in humans. AIMS: Little is known about the impact of the long-term effects of chronic exposure to low doses of THC in adolescent compared to adult rodents. METHODS: THC (1mg/kg...

Evaluation of Biased and Balanced Salvinorin A Analogs in Preclinical Models of Pain

Frontiers in Neuroscience July 21, 2020 Kelly F Paton, Andrew Biggerstaff, Sophia Kaska et al.

In the search for safer, non-addictive analgesics, kappa opioid receptor (KOPr) agonists are a potential target, as unlike mu-opioid analgesics, they do not have abuse potential. Salvinorin A (SalA) is a potent and selective KOPr agonist, however, clinical utility is limited by the short duration of action and aversive side effects. Biasing KOPr signaling toward G-protein activation has been...